報 告  人⚃：Prof. Bing Zhang，Baylor College of Medicine, Houston, TX, USA

報告時間：2018年11月13日 11:00am-12:00 pm
報告地點🤱：閔行校區生物藥學樓2-116

聯 系  人🙎🏻：李婧😯， jing.li@sjtu.edu.cn

報告人介紹： Dr. Zhang is Professor, McNair Scholar of Molecular and Human Genetics at the Baylor College of Medicine in Houston, Texas. He received his PhD degree in Genetics from the Chinese Academy of Sciences followed by a postdoctoral training in bioinformatics at the Oak Ridge National Laboratory. Before joining Baylor College of Medicine in August 2016, he had been a faculty member in the Department of Biomedical Informatics at the Vanderbilt University for ten years. Dr. Zhang’s research program focuses on integrating genomic and proteomic data to better understand cancer biology. He has more than 80 publications in the areas of bioinformatics, proteomics and cancer systems biology. He has served as principal investigator, bioinformatics director, or co-investigator on more than ten federal grants. He serves frequently as program committee member in international conferences and reviewer for NIH panels. He also serves on the editorial board of Molecular & Cellular Proteomics and Clinical Proteomics.

報告摘要：

We performed an unprecedented characterization of human colon cancer and paired normal samples with comprehensive integration of data from seven omics platforms. We confirmed previously described benefits of protegenomic integration in human cancer studies and further demonstrated its utility in revealing novel therapeutic opportunities. Comparative proteomic and phosphoproteomic analyses of paired tumor and adjacent normal samples produced a comprehensive catalogue of colon cancer-associated proteins, phosphosites, and kinase activities, including known and putative biomarkers, drug targets, and cancer-testis (CT) antigens. Proteogenomic integration not only prioritized genomically inferred targets such as somatic copy number drivers and somatic mutation-derived neoantigens, but also yielded unexpected discovery of signaling and metabolic targets for different colon cancer subtypes.